Prediabetes and diabetes are main causes of morbidity and mortality within the United States and are rising in prevalence as much as 45% of the inhabitants over the previous 50 years. Current pointers from the ADA advocate specializing in power steadiness, portion sizes, and weight reduction whereas cautioning that no splendid macronutrient composition has been decided. The pointers additionally don’t advocate intermittent fasting.
In distinction, we report three instances of a substantial discount in A1C with out clinically important weight reduction utilizing a distinctive, patient-centered program that makes use of low carbohydrate diets with intermittent fasting. These outcomes name into query the position of weight discount within the administration of diabetes whereas highlighting the distinctive significance of carbohydrate restriction and intermittent fasting.
In this examine, we show a case collection of three sufferers with a substantial discount in A1C and considerably decreasing the necessity for pharmacotherapy with out clinically important weight reduction. Although anecdotal, these outcomes name into query the emphasis of ADA on weight discount and power consumption discount for the administration of diabetes.
Graphene Quantum Dot-Decorated Luminescent Porous Silicon Dressing for Theranostics of Diabetic Wounds
Diabetic wound therapeutic is very fascinating however stays a nice problem owing to the continual harm of extra reactive oxygen species (ROS) and degradation of therapeutic peptide medication by over-expressed matrix metalloproteinase (MMP). Herein, we developed a stimuli-responsive sensible dressing for theranostics of diabetic wound utilizing graphene quantum dots-decorated luminescent porous silicon (GQDs@PSi), which was additional loaded with peptide and embedded in chitosan (CS) movie.
The confinement of GQDs in nanochannels of PSi endowed GQDs@PSi with environment friendly fluorescence resonance power switch (FRET) impact, resulting in preliminary crimson fluorescence of PSi with full quench of GQD’s blue fluorescence. Furthermore, the ornament of GQDs on PSi floor considerably enhanced the loading capability for peptide medication together with epidermal progress issue (EGF) and insulin (Ins) which might promote diabetic wound therapeutic.
The peptides coloaded in GQDs@PSi exhibited sustained launch habits and could possibly be protected in presence of MMP owing to dimension exclusion of PSi’s nanochannels. As H2O2-triggered oxidation of PSi result in weakened FRET impact and degradation of PSi, GQDs@PSi demonstrated H2O2-responsive ratiometric fluorescence change (from crimson PSi to blue GQDs) and drug launch habits. In mixture with CS’s degradation within the acidic and oxidation microenvironment, the sensible dressing additionally confirmed stimuli-responsive drug launch towards barely acid and extremely oxidative situations in diabetic wound.
In vitro and in vivo outcomes demonstrated the sensible dressing enhanced the proliferation and migration of cells in addition to considerably healed diabetic wounds. Real-time indicating of the exacerbation or therapeutic of diabetic wounds was additionally realized utilizing the speed of fluorescent discoloration of the dressing.
Intraglomerular dysfunction predicts kidney failure in sort 2 diabetes
No longitudinal knowledge hyperlink intraglomerular hemodynamic dysfunction with end-stage kidney illness (ESKD) in individuals with sort 2 diabetes (T2D). Afferent (RA) and efferent (RE) arteriolar tone and intraglomerular strain (PGLO) will not be immediately measurable in people however are estimable from glomerular filtration charge (GFR), renal plasma circulation (RPF), blood strain, hematocrit, and plasma oncotic strain.
We examined the affiliation of the RA/RE ratio and PGLO with ESKD incidence in 237 Pima Indian individuals with T2D who underwent serial measures of GFR (iothalamate) and RPF (p-aminohippurate). Their affiliation with kidney structural lesions was additionally examined in a subset of 111 contributors. Of the 237 contributors (imply age 42 years, diabetes length 11 years, GFR 153 ml/min, median ACR 36 mg/g), 69 progressed to ESKD throughout median follow-up of 17.5 years.
In latent class evaluation, distinct trajectories characterised by rising RA/RE ratio (HR: 4.60, 95% CI 2.55-8.31) or elevated PGLO adopted by a speedy decline (HR: 2.96, 95% CI 1.45-6.02) strongly predicted incident ESKD. PGLO (R2=21%, p<0.0001) and RA/RE (R2=15%, p<0.0001) additionally correlated with mesangial fractional quantity, a structural predictor of DKD development.In conclusion, intraglomerular hemodynamic parameters related strongly with incident ESKD and correlated with structural lesions of DKD.
Data from a pooled submit hoc evaluation of 14 placebo-controlled, dapagliflozin remedy research in sufferers with sort 2 diabetes with and with out anemia at baseline
Dapagliflozin is a extremely selective sodium-glucose cotransporter 2 inhibitor related to stabilization of estimated glomerular filtration charge (eGFR); reductions in glycated hemoglobin (HbA1c), systolic blood strain, physique weight, and albuminuria; and a small and constant enhance in hematocrit [1], [2], [3], [4]. This knowledge set is predicated on the related article [5] analyzing knowledge from 5325 sufferers with sort 2 diabetes from 14 placebo-controlled, section 3 (one section 2/3), double-blind dapagliflozin remedy research of 24-104 weeks’ length.
Data on dapagliflozin’s results (vs. placebo) on hemoglobin (Hb), hematocrit, serum albumin, serum whole protein concentrations, urine albumin/creatinine ratio, eGFR, coronary heart charge, blood strain, physique weight, and security in sufferers with sort 2 diabetes with and with out anemia have been pooled and analyzed. Patients have been divided into two teams in accordance with baseline Hb ranges: anemia (Hb <13 g/dL in males and <12 g/dL in girls) and no anemia.
Some biomarkers related to erythropoiesis and the presence of anemia, resembling iron, transferrin, ferritin, reticulocytes, and hepcidin, weren’t included within the authentic research and due to this fact knowledge for these biomarkers weren’t obtainable. Descriptive statistics have been used for baseline traits and security knowledge and a longitudinal repeated-measures combined mannequin for efficacy knowledge.
Gene Knock-Out HR Targeting Vector [MCS1-EF1a-RFP-T2A-Hygro-pA-MCS2] |
|||
| HR510PA-1 | SBI | 10 ug | 933 EUR |
B2M Knockout Jurkat Cell Line |
|||
| 78342 | BPS Bioscience | 2 vials | 6500 EUR |
|
Description: B2M (Beta-2-Microglobulin) has been genetically removed by CRISPR/Cas9 genome editing from Jurkat cells. |
|||
TCR Knockout Jurkat Cell Line |
|||
| 78539 | BPS Bioscience | 2 vials | 6500 EUR |
|
Description: The TCR Knockout Jurkat cell line was generated by CRISPR/Cas9 genome editing to remove the TRAC (T-Cell Receptor Alpha Constant) and TRBC1 (T-Cell Receptor Beta Constant 1) domains of the TCRα and β chains. |
|||
Rrad 3'UTR GFP Stable Cell Line |
|||
| TU168183 | ABM | 1.0 ml | Ask for price |
RRAD 3'UTR GFP Stable Cell Line |
|||
| TU072380 | ABM | 1.0 ml | 1672.8 EUR |
Rrad 3'UTR GFP Stable Cell Line |
|||
| TU269725 | ABM | 1.0 ml | Ask for price |
B2M Knockout THP-1 Cell Line |
|||
| 78389 | BPS Bioscience | 2 vials | 6500 EUR |
|
Description: B2M (Beta-2-Microglobulin) has been genetically removed by CRISPR/Cas9 genome editing from THP-1 cells. |
|||
CIITA Knockout THP-1 Cell Line |
|||
| 78390 | BPS Bioscience | 2 vials | 6500 EUR |
|
Description: CIITA (Class II Transactivator) has been genetically removed from THP-1 cells using CRISPR/Cas9 genome editing. |
|||
Basic HR Targeting Vector [MCS1-LoxP-MCS2-MCS3-pA-LoxP-MCS4] for Gene Knock-In/Out |
|||
| HR100PA-1 | SBI | 10 ug | 868 EUR |
TCR/B2M Knockout Jurkat Cell Line |
|||
| 78552 | BPS Bioscience | 2 vials | 8645 EUR |
|
Description: This cell line is a double knockout of TCR (T Cell Receptor) and B2M (Beta-2-Microglobulin). First, the TRAC (T-Cell Receptor Alpha Constant) and the TRBC1 (T-Cell Receptor Beta Constant 1) domains of the TCRα/β chains were genetically removed by CRISPR/Cas9 genome editing from Jurkat cells to generate the TCR Knockout Jurkat cell Line (BPS Bioscience #78539). These TCR knockout cells were then used to generate a new cell line in which B2M was also genetically removed by CRISPR/Cas9 genome editing. |
|||
293AD Cell Line |
|||
| AD-100 | Cell Biolabs | 1 vial | 553.2 EUR |
|
Description: The 293AD Cell Line is derived from the parental 293 cells but selected for attributes that increase adenovirus production, including firmer attachment and larger surface area. |
|||
293AAV Cell Line |
|||
| AAV-100 | Cell Biolabs | 1 vial | 609.6 EUR |
|
Description: The 293AAV Cell Line is derived from the parental 293 cells but selected for attributes that increase AAV production, including firmer attachment and larger surface area. |
|||
293LTV Cell Line |
|||
| LTV-100 | Cell Biolabs | 1 vial | 609.6 EUR |
|
Description: The 293LTV Cell Line is derived from the parental 293 cells but selected for attributes that increase lentiviral production, including fimrer attachment and larger surface area. |
|||
293RTV Cell Line |
|||
| RV-100 | Cell Biolabs | 1 vial | 609.6 EUR |
|
Description: The 293RTV Cell Line is derived from the parental 293 cells but selected for attributes that increase retroviral production, including fimrer attachment and larger surface area. |
|||
Rrad 3'UTR Luciferase Stable Cell Line |
|||
| TU118183 | ABM | 1.0 ml | Ask for price |
RRAD 3'UTR Luciferase Stable Cell Line |
|||
| TU022380 | ABM | 1.0 ml | 1672.8 EUR |
Rrad 3'UTR Luciferase Stable Cell Line |
|||
| TU219725 | ABM | 1.0 ml | Ask for price |
293/GFP Cell Line |
|||
| AKR-200 | Cell Biolabs | 1 vial | 686.4 EUR |
|
Description: 293/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line. |
|||
FCGR2A (CD32A) Knockout Jurkat Cell Line |
|||
| 78549 | BPS Bioscience | 2 vials | 6500 EUR |
|
Description: The FCGR2A Knockout Jurkat cell line was generated by CRISPR/Cas9 genome editing to remove FCGR2A (CD32A), the gene encoding protein FcγRIIa (Fragment crystallizable gamma receptor II a, also known as FcGRIIa, Fc-gamma-RIIa, and CD32A). |
|||
A549/GFP Cell Line |
|||
| AKR-209 | Cell Biolabs | 1 vial | 686.4 EUR |
|
Description: A549/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line. |
|||
HeLa/GFP Cell Line |
|||
| AKR-213 | Cell Biolabs | 1 vial | 686.4 EUR |
|
Description: HeLa/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line. |
|||
293/Cas9 Cell Line |
|||
| AKR-5110 | Cell Biolabs | 1 vial | 686.4 EUR |
HeLa/Cas9 Cell Line |
|||
| AKR-5111 | Cell Biolabs | 1 vial | 686.4 EUR |
Human 293T Whole Cell Lysate |
|||
| LYSATE0032 | BosterBio | 200ug | 180 EUR |
|
Description: This cell lysate is prepared from human 293T using Boster's RIPA Lysis Buffer (AR0105) using a standard whole cell lysate protocol. The concentration was determined using the BCA assay process and then diluted using Dithiothreitol (DTT) and a reducing SDS sample loading buffer, heated for 5 minutes at 100˚C. |
|||
NIH3T3/GFP Cell Line |
|||
| AKR-214 | Cell Biolabs | 1 vial | 686.4 EUR |
|
Description: NIH3T3/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line. |
|||
NIH3T3/Cas9 Cell Line |
|||
| AKR-5104 | Cell Biolabs | 1 vial | 686.4 EUR |
TARGATT? Knock-in iPSC Quick Knockin Kit |
|||
| AST-1101 | Applied StemCell | 1 Kit | Ask for price |
|
Description: 12 month |
|||
MCF-7/Luc Cell Line |
|||
| AKR-234 | Cell Biolabs | 1 vial | 686.4 EUR |
|
Description: MCF-7/Luc Cell Line stably expresses luciferase and otherwise exhibits the same characteristics of the parental cell line. |
|||
SKOV-3/Luc Cell Line |
|||
| AKR-232 | Cell Biolabs | 1 vial | 686.4 EUR |
|
Description: SKOV-3/Luc Cell Line stably expresses luciferase and otherwise exhibits the same characteristics of the parental cell line. |
|||
B2M/CIITA Double Knockout THP-1 Cell Line |
|||
| 78391 | BPS Bioscience | 2 vials | 9500 EUR |
|
Description: Both B2M (Beta-2-Microglobulin) and CIITA (Class II Transactivator) have been genetically removed from THP-1 cells using CRISPR/Cas9 genome editing. |
|||
OVCAR-5/RFP Cell Line |
|||
| AKR-254 | Cell Biolabs | 1 vial | 686.4 EUR |
|
Description: OVCAR-5/RFP Cell Line stably expresses RFP and otherwise exhibits the same characteristics of the parental cell line. |
|||
AAVS1 Positive Control EGIP 293T Reporter Cell Line |
|||
| CAS606A-1 | SBI | 1 Vial | 726 EUR |
B2M Knockout NFAT Luciferase Reporter Jurkat Cell Line |
|||
| 78363 | BPS Bioscience | 2 vials | 11095 EUR |
|
Description: B2M (Beta-2-Microglobulin) has been genetically removed by CRISPR/Cas9 genome editing from NFAT Luciferase Reporter Jurkat cells. Expression of the firefly luciferase gene is driven by NFAT response elements located upstream of the minimal TATA promoter. Activation of the NFAT signaling pathway in these cells can be monitored by measuring luciferase activity. |
|||
RRAD sgRNA CRISPR Lentivector set (Human) |
|||
| K2069901 | ABM | 3 x 1.0 ug | 406.8 EUR |
TCR Knockout NFAT-Luciferase Reporter Jurkat Cell Line |
|||
| 78556 | BPS Bioscience | 2 vials | 12205 EUR |
|
Description: This cell line is a knockout of TCR (T Cell Receptor). The TRAC (T-Cell Receptor Alpha Constant) and TRBC1 (T-Cell Receptor Beta Constant 1) domains of the TCRα/β chains were genetically removed by CRISPR/Cas9 genome editing from recombinant Jurkat cells stably expressing the firefly luciferase gene under the control of NFAT response elements.This cell line has been functionally validated and does not respond to anti-CD3 agonist antibodies, as opposed to parental NFAT-Luciferase Reporter Jurkat cells (BPS Bioscience #60621). |
|||
TARGATT? Knock-in iPSC Genotyping Kit |
|||
| AST-1102 | Applied StemCell | 1 Kit | Ask for price |
|
Description: 12 month |
|||
TCR/B2M Knockout NFAT Luciferase Reporter Jurkat Cell Line |
|||
| 78557 | BPS Bioscience | 2 vials | 16695 EUR |
|
Description: This cell line is a double knockout of TCR (T Cell Receptor) and B2M (Beta-2-Microglobulin). First, the TRAC (T-Cell Receptor Alpha Constant) and the TRBC1 (T-Cell Receptor Beta Constant 1) domains of the TCRα/β chains were genetically removed by CRISPR/Cas9 genome editing from NFAT Luciferase Reporter Jurkat cells to generate the TCR Knockout NFAT Luciferase Reporter Jurkat cell Line (BPS Bioscience #78556). These TCR knockout cells were used to generate a new cell line in which B2M was also genetically removed by CRISPR/Cas9 genome editing. _x000D_Expression of the firefly luciferase gene is driven by NFAT response elements located upstream of the minimal TATA promoter. Activation of the NFAT signaling pathway in these cells can be monitored by measuring luciferase activity. |
|||
Platinum-E Retroviral Packaging Cell Line, Ecotropic |
|||
| RV-101 | Cell Biolabs | 1 vial | 1104 EUR |
|
Description: Conventional cells used for retrovirus packaging, such as those based on NIH3T3 cells, have limited stability and produce relatively low yields of retrovirus, mainly due to the poor expression of retroviral structure proteins (gag, pol and env) in the cells. The Platinum Retroviral Packaging Cell Lines are based on the 293T cell line. They exhibit longer stability and produce higher yields of retroviral structure proteins. Plat-E cells contain gag, pol and env genes, allowing retroviral packaging with a single plasmid transfection. |
|||
Platinum-GP Retroviral Packaging Cell Line, Pantropic |
|||
| RV-103 | Cell Biolabs | 1 vial | 1104 EUR |
|
Description: Conventional cells used for retrovirus packaging, such as those based on NIH3T3 cells, have limited stability and produce relatively low yields of retrovirus, mainly due to the poor expression of retroviral structure proteins (gag, pol and env) in the cells. The Platinum Retroviral Packaging Cell Lines are based on the 293T cell line. They exhibit longer stability and produce higher yields of retroviral structure proteins. Plat-GP cells contain the gag and pol genes required for retroviral packaging; an expression vector is co-transfected with a VSVG envelope vector. |
|||
Platinum-A Retroviral Packaging Cell Line, Amphotropic |
|||
| RV-102 | Cell Biolabs | 1 vial | 1104 EUR |
|
Description: Conventional cells used for retrovirus packaging, such as those based on NIH3T3 cells, have limited stability and produce relatively low yields of retrovirus, mainly due to the poor expression of retroviral structure proteins (gag, pol and env) in the cells. The Platinum Retroviral Packaging Cell Lines are based on the 293T cell line. They exhibit longer stability and produce higher yields of retroviral structure proteins. Plat-A cells contain gag, pol and env genes, allowing retroviral packaging with a single plasmid transfection. |
|||
Total Protein - Murine Embryonic Stem Cell Line D3 |
|||
| CBA-305 | Cell Biolabs | 500 ?g | 414 EUR |
|
Description:
|
|||
RRAD sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
| K2069902 | ABM | 1.0 ug DNA | 184.8 EUR |
RRAD sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
| K2069903 | ABM | 1.0 ug DNA | 184.8 EUR |
RRAD sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
| K2069904 | ABM | 1.0 ug DNA | 184.8 EUR |
Gene Knock-Out HR Targeting Vector w/Single Selection Marker (Blasticidin) and Negative Selection (TK) Against Random Integration |
|||
| HR720PA-1 | SBI | 10 µg | 1071 EUR |
Gene Knock-Out HR Targeting Vector w/Dual Selection Markers (GFP+Puro) and Negative Selection (TK) Against Random Integration |
|||
| HR700PA-1 | SBI | 10 µg | 1071 EUR |
Gene Knock-Out HR Targeting Vector w/Dual Selection Markers (RFP+Hygro) and Negative Selection (TK) Against Random Integration |
|||
| HR710PA-1 | SBI | 10 µg | 1071 EUR |
Gene Knock-Out HR Targeting Vector with TK selection [MCS1-LoxP-EF1α-GFP-T2A-Puro-P2A-hsvTK-pA-LoxP-MCS2] |
|||
| HR210PA-1 | SBI | 10 ug | 1071 EUR |
Rrad/ Rat Rrad ELISA Kit |
|||
| ELI-14921r | Lifescience Market | 96 Tests | 1063.2 EUR |
RRAD ELISA KIT|Human |
|||
| EF005507 | Lifescience Market | 96 Tests | 826.8 EUR |
Rrad sgRNA CRISPR Lentivector set (Rat) |
|||
| K7052701 | ABM | 3 x 1.0 ug | 406.8 EUR |
Human RRAD shRNA Plasmid |
|||
| 20-abx954199 | Abbexa |
|
|
Rrad sgRNA CRISPR Lentivector set (Mouse) |
|||
| K3480701 | ABM | 3 x 1.0 ug | 406.8 EUR |
RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
| K2069905 | ABM | 3 x 1.0 ug | 451.2 EUR |
RRAD Recombinant Protein (Human) |
|||
| RP095493 | ABM | 100 ug | Ask for price |
RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
|||
| K2069906 | ABM | 1.0 ug DNA | 200.4 EUR |
RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
|||
| K2069907 | ABM | 1.0 ug DNA | 200.4 EUR |
RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
|||
| K2069908 | ABM | 1.0 ug DNA | 200.4 EUR |
Rrad sgRNA CRISPR Lentivector (Rat) (Target 1) |
|||
| K7052702 | ABM | 1.0 ug DNA | 184.8 EUR |
Rrad sgRNA CRISPR Lentivector (Rat) (Target 2) |
|||
| K7052703 | ABM | 1.0 ug DNA | 184.8 EUR |
Rrad sgRNA CRISPR Lentivector (Rat) (Target 3) |
|||
| K7052704 | ABM | 1.0 ug DNA | 184.8 EUR |
RRAD ORF Vector (Human) (pORF) |
|||
| ORF031832 | ABM | 1.0 ug DNA | 486 EUR |
Rrad sgRNA CRISPR Lentivector (Mouse) (Target 1) |
|||
| K3480702 | ABM | 1.0 ug DNA | 184.8 EUR |
Rrad sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|||
| K3480703 | ABM | 1.0 ug DNA | 184.8 EUR |
Rrad sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|||
| K3480704 | ABM | 1.0 ug DNA | 184.8 EUR |
RRAD siRNA |
|||
| 20-abx932133 | Abbexa |
|
|
RRAD Peptide |
|||
| 43-008P | ProSci | 0.1 mg | 405.6 EUR |
|
Description: RRAD Peptide |
|||
RRAD Antibody |
|||
| 37229-100ul | SAB | 100ul | 302.4 EUR |
RRAD antibody |
|||
| 70R-5797 | Fitzgerald | 50 ug | 560.4 EUR |
|
Description: Rabbit polyclonal RRAD antibody raised against the middle region of RRAD |
|||
RRAD antibody |
|||
| 70R-5798 | Fitzgerald | 50 ug | 560.4 EUR |
|
Description: Rabbit polyclonal RRAD antibody raised against the middle region of RRAD |
|||
RRAD antibody |
|||
| 70R-50359 | Fitzgerald | 100 ul | 292.8 EUR |
|
Description: Purified Polyclonal RRAD antibody |
|||
RRAD Antibody |
|||
| 1-CSB-PA003910 | Cusabio |
|
|
|
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human. This antibody is Unconjugated. Tested in the following application: WB, IHC, IF, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.IF:1/200-1/1000.ELISA:1/20000 |
|||
RRAD Antibody |
|||
| CSB-PA233809- | Cusabio | each | 402 EUR |
|
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF;WB:1:500-1:3000, IHC:1:50-1:100, IF:1:100-1:500 |
|||
RRAD Antibody |
|||
| CSB-PA233809-100ul | Cusabio | 100ul | 379.2 EUR |
|
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF;WB:1:500-1:3000, IHC:1:50-1:100, IF:1:100-1:500 |
|||
RRAD Antibody |
|||
| 1-CSB-PA248209 | Cusabio |
|
|
|
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:5000, IHC:1:25-1:100 |
|||
RRAD Antibody |
|||
| 1-CSB-PA779820 | Cusabio |
|
|
|
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:50-1:200 |
|||
RRAD Antibody |
|||
| R34275-100UG | NSJ Bioreagents | 100 ug | 339.15 EUR |
|
Description: Additional name(s) for this target protein: Ras-related associated with diabetes |
|||
hspCas9 AAVS1 Safe Harbor Knock-in Donor (AAVS1-SA-puro-EF1-hspCas9) |
|||
| CAS620A-1 | SBI | 10 ug | 1106 EUR |
CytoSelect Cell Transformation Assay (Cell Recovery Compatible), Colorimetric |
|||
| CBA-135 | Cell Biolabs | 96 assays | 985.2 EUR |
|
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis. |
|||
CytoSelect Cell Transformation Assay (Cell Recovery Compatible), Colorimetric |
|||
| CBA-135-5 | Cell Biolabs | 5 x 96 assays | 4027.2 EUR |
|
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis. |
|||
CytoSelect Cell Transformation Assay (Cell Recovery Compatible), Fluorometric |
|||
| CBA-140 | Cell Biolabs | 96 assays | 1027.2 EUR |
|
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis. |
|||
CytoSelect Cell Transformation Assay (Cell Recovery Compatible), Fluorometric |
|||
| CBA-140-5 | Cell Biolabs | 5 x 96 assays | 4179.6 EUR |
|
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis. |
|||
StemTAG Stem Cell Colony Formation Assay (Cell Recovery Compatible) |
|||
| CBA-325 | Cell Biolabs | 96 assays | 1027.2 EUR |
|
Description: Our StemTAG 96-Well Stem Cell Colony Formation Assay provides a high-throughput method to quantify ES cells in just 7-10 days, and no manual cell counting is required. Once colonies are formed, they may be analyzed in three different ways: 1. Lyse cells, then quantify in a fluorescence plate reader using dye included in the kit; 2. Lyse cells, then quantify alkaline phosphatase activity using reagents provided; or 3. Recover colonies from matrix for further culture or analysis. |
|||
StemTAG Stem Cell Colony Formation Assay (Cell Recovery Compatible) |
|||
| CBA-325-5 | Cell Biolabs | 5 x 96 assays | 4033.2 EUR |
|
Description: Our StemTAG 96-Well Stem Cell Colony Formation Assay provides a high-throughput method to quantify ES cells in just 7-10 days, and no manual cell counting is required. Once colonies are formed, they may be analyzed in three different ways: 1. Lyse cells, then quantify in a fluorescence plate reader using dye included in the kit; 2. Lyse cells, then quantify alkaline phosphatase activity using reagents provided; or 3. Recover colonies from matrix for further culture or analysis. |
|||
CytoSelect Cell Transformation Assay (Cell Recovery Compatible), Colorimetric, Trial Size |
|||
| CBA-135-T | Cell Biolabs | 24 assays | 518.4 EUR |
|
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis. |
|||
PinPoint-FC 293T Platform Cell Line for Targeted Gene Insertion (with PinPoint site already placed) |
|||
| PIN320A-1 | SBI | >2x10^5 cells | 2987 EUR |
pGreenFire 2.0 AP-1 clonal 293T reporter cell line (pGF2-AP1-rFluc-T2A-GFP-mPGK-Puro) |
|||
| TR452C-P | SBI | >2 x 10^6 cells | 3080 EUR |
CytoSelect 96-Well Cell Transformation Assay (Cell Recovery Compatible, Fluorometric), Trial Size |
|||
| CBA-140-T | Cell Biolabs | 24 assays | 547.2 EUR |
|
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis. |
|||
Cas9 (CRISPR Associated Protein 9) ELISA Kit |
|||
| PRB-5079 | Cell Biolabs | 96 assays | 686.4 EUR |
Collagen-based Cell Contraction Assay |
|||
| CBA-201 | Cell Biolabs | 24 assays | 582 EUR |
|
Description: Cell Biolabs? Collagen-based Contraction Assay Kit provides a simple system to assess cell contractivity in vitro and screen cell contraction mediators. Each kit provides sufficient quantities to perform up to 24 assays in a 24-well plate. The kit can be also used in culturing cells in 3D collagen matrix. |
|||
CytoSelect MTT Cell Proliferation Assay |
|||
| CBA-252 | Cell Biolabs | 960 assays | 490.8 EUR |
|
Description: Cell Biolabs? CytoSelect MTT Cell Proliferation Assay provides a colorimetric format for measuring and monitoring cell proliferation. The kit contains sufficient reagents for the evaluation of 960 assays in 96-well plates or 192 assays in 24-well plates. Cells can be plated and then treated with compounds or agents that affect proliferation. Cells are then detected with the proliferation reagent, which is converted in live cells from the yellow tetrazole MTT to the purple formazan form by a cellular reductase (Figure 1). An increase in cell proliferation is accompanied by an increased signal, while a decrease in cell proliferation (and signal) can indicate the toxic effects of compounds or suboptimal culture conditions. The assay principles are basic and can be applied to most eukaryotic cell lines, including adherent and non-adherent cells and certain tissues. This cell proliferation reagent can be used to detect proliferation in bacteria, yeast, fungi, protozoa as well as cultured mammalian and piscine cells. |
|||
CRISPR/Cas9 Kinase Knockout Lentivirus Library (Array Format) |
|||
| 78487 | BPS Bioscience | 200 µl x 649 | 7700 EUR |
|
Description: The CRISPR/Cas9 Kinase Knockout Lentivirus Library (Array Format) targets 619 human kinases and pseudo-kinases.bpsbioscience.com/media/wysiwyg/Kinases/Kinase_Library_-_List_Kinases_Pseudokinases_06-15-2022.xlsx Download the table to view all available kinases. The Array consists of a series of vials, with each vial containing a mixture of integrating CRISPR/Cas9 lentiviral particles targeting 5 sgRNAs for a specific gene (1 vial per gene, 5 sgRNAs per gene). The Array also includes a total of 150 control sgRNAs that do not target any gene (combined into 30 vials containing 5 control sgRNAs per vial). Thus, the Array contains a total of 649 vials and 3,245 sgRNAs.The lentiviruses are replication incompetent, VSV-G pseudotyped lentiviral particles ready to infect almost all types of mammalian cells, including primary and non-dividing cells. The SIN (self-inactivation) lentiviral backbone contains the Cas9 gene (Streptococcus pyogenes CRISPR associated protein 9) driven by an EF1a promoter, an sgRNA driven by a U6 promoter, and a puromycin selection marker.The lentiviruses integrate randomly into the cellular genome to express both Cas9 and the sgRNAs. Because the lentiviruses contain Cas9, they can be used in any target cell regardless of whether the cells already express Cas9. Puromycin selection ensures high expression of both Cas9 and the sgRNAs. Knockout efficiencies will depend on the cell type and the gene of interest. Stable CRISPR/Cas9 knockout cell lines can also be generated following limiting dilution.The library is delivered with a User Manual booklet. |
|||
Radius 24-Well Cell Migration Assay |
|||
| CBA-125 | Cell Biolabs | 24 assays | 602.4 EUR |
|
Description: The Radius Cell Migration Assay provides a unique alternative to conventional cell migration assays using the Boyden chamber. Unlike Boyden chamber assays which may only be analyzed at endpoint, the Radius assay uses a proprietary cell culture plate containing a carefully-defined biocompatible hydrogel (Radius gel) spot centralized at the bottom of each well. When cells are seeded in the well, they will attach everywhere except on the Radius gel, creating a cell-free zone. Following cell seeding the Radius gel is removed, allowing migratory cells to move across the area and close the gap. |
|||
Radius 24-Well Cell Migration Assay |
|||
| CBA-125-5 | Cell Biolabs | 5 x 24 assays | 2362.8 EUR |
|
Description: The Radius Cell Migration Assay provides a unique alternative to conventional cell migration assays using the Boyden chamber. Unlike Boyden chamber assays which may only be analyzed at endpoint, the Radius assay uses a proprietary cell culture plate containing a carefully-defined biocompatible hydrogel (Radius gel) spot centralized at the bottom of each well. When cells are seeded in the well, they will attach everywhere except on the Radius gel, creating a cell-free zone. Following cell seeding the Radius gel is removed, allowing migratory cells to move across the area and close the gap. |
|||
Radius 96-Well Cell Migration Assay |
|||
| CBA-126 | Cell Biolabs | 96 assays | 686.4 EUR |
|
Description: The Radius Cell Migration Assay provides a unique alternative to conventional cell migration assays using the Boyden chamber. Unlike Boyden chamber assays which may only be analyzed at endpoint, the Radius assay uses a proprietary cell culture plate containing a carefully-defined biocompatible hydrogel (Radius gel) spot centralized at the bottom of each well. When cells are seeded in the well, they will attach everywhere except on the Radius gel, creating a cell-free zone. Following cell seeding the Radius gel is removed, allowing migratory cells to move across the area and close the gap. |
|||
Radius 96-Well Cell Migration Assay |
|||
| CBA-126-5 | Cell Biolabs | 5 x 96 assays | 2697.6 EUR |
|
Description: The Radius Cell Migration Assay provides a unique alternative to conventional cell migration assays using the Boyden chamber. Unlike Boyden chamber assays which may only be analyzed at endpoint, the Radius assay uses a proprietary cell culture plate containing a carefully-defined biocompatible hydrogel (Radius gel) spot centralized at the bottom of each well. When cells are seeded in the well, they will attach everywhere except on the Radius gel, creating a cell-free zone. Following cell seeding the Radius gel is removed, allowing migratory cells to move across the area and close the gap. |
|||
Radius 384-Well Cell Migration Assay |
|||
| CBA-127 | Cell Biolabs | 384 assays | 721.2 EUR |
|
Description: The Radius Cell Migration Assay provides a unique alternative to conventional cell migration assays using the Boyden chamber. Unlike Boyden chamber assays which may only be analyzed at endpoint, the Radius assay uses a proprietary cell culture plate containing a carefully-defined biocompatible hydrogel (Radius gel) spot centralized at the bottom of each well. When cells are seeded in the well, they will attach everywhere except on the Radius gel, creating a cell-free zone. Following cell seeding the Radius gel is removed, allowing migratory cells to move across the area and close the gap. |
|||
Radius 384-Well Cell Migration Assay |
|||
| CBA-127-5 | Cell Biolabs | 5 x 384 wells | 2802 EUR |
|
Description: The Radius Cell Migration Assay provides a unique alternative to conventional cell migration assays using the Boyden chamber. Unlike Boyden chamber assays which may only be analyzed at endpoint, the Radius assay uses a proprietary cell culture plate containing a carefully-defined biocompatible hydrogel (Radius gel) spot centralized at the bottom of each well. When cells are seeded in the well, they will attach everywhere except on the Radius gel, creating a cell-free zone. Following cell seeding the Radius gel is removed, allowing migratory cells to move across the area and close the gap. |
|||
Radius 48-Well Cell Migration Assay |
|||
| CBA-5037 | Cell Biolabs | 48 assays | 622.8 EUR |
|
Description: The Radius Cell Migration Assay provides a unique alternative to conventional cell migration assays using the Boyden chamber. Unlike Boyden chamber assays which may only be analyzed at endpoint, the Radius assay uses a proprietary cell culture plate containing a carefully-defined biocompatible hydrogel (Radius gel) spot centralized at the bottom of each well. When cells are seeded in the well, they will attach everywhere except on the Radius gel, creating a cell-free zone. Following cell seeding the Radius gel is removed, allowing migratory cells to move across the area and close the gap. |
|||
Radius 48-Well Cell Migration Assay |
|||
| CBA-5037-5 | Cell Biolabs | 5 x 48 assays | 2454 EUR |
|
Description: The Radius Cell Migration Assay provides a unique alternative to conventional cell migration assays using the Boyden chamber. Unlike Boyden chamber assays which may only be analyzed at endpoint, the Radius assay uses a proprietary cell culture plate containing a carefully-defined biocompatible hydrogel (Radius gel) spot centralized at the bottom of each well. When cells are seeded in the well, they will attach everywhere except on the Radius gel, creating a cell-free zone. Following cell seeding the Radius gel is removed, allowing migratory cells to move across the area and close the gap. |
|||
HIF-1 Alpha Cell Based ELISA Kit |
|||
| CBA-281 | Cell Biolabs | 96 assays | 734.4 EUR |
|
Description: Cell Biolabs? HIF-1 Cell Based ELISA Kit is an immunoassay developed for rapid detection of HIF-1 Alpha in fixed cells. Cells on a microplate are stimulated for HIF-1 Alpha stabilization, fixed, permeabilized, and then neutralized in the well. HIF-1 Alpha is then detected with an anti-HIF-1 alpha antibody followed by an HRP conjugated secondary antibody. Each kit provides sufficient reagents to perform up to a total of 96 assays and can detect HIF-1 Alpha from human, mouse, or rat. |
|||
Cas13a (CRISPR Associated Protein 13a, C2c2) ELISA Kit |
|||
| PRB-5091 | Cell Biolabs | 96 assays | 686.4 EUR |
CytoSelect BrdU Cell Proliferation ELISA Kit |
|||
| CBA-251 | Cell Biolabs | 96 assays | 637.2 EUR |
|
Description: The CytoSelect BrdU Cell Proliferation ELISA Kit detects BrdU incorporated into cellular DNA during cell proliferation using an anti-BrdU antibody. When cells are incubated in media containing BrdU, the pyrimidine analog is incorporated in place of thymidine into the newly synthesized DNA of proliferating cells. Once the labeling media is removed, the cells are fixed and the DNA is denatured in one step with a fix/denature solution (denaturation of the DNA is necessary to improve the accessibility of the incorporated BrdU for detection). Then an anti-BrdU mouse monoclonal antibody is added followed by an HRP conjugated secondary antibody to detect the incorporated BrdU. The magnitude of the absorbance for the developed color is proportional to the quantity of BrdU incorporated into cells and can be directly correlated to cell proliferation. |
|||
pGreenFire 2.0 TCF/LEF clonal 293T reporter cell line (pGF2-TCF/LEF-rFluc-T2A-GFP-mPGK-Puro) |
|||
| TR413C-P | SBI | >2 x 10^6 cells | 3080 EUR |
CytoSelect 96-well Cell Transformation Assay |
|||
| CBA-130 | Cell Biolabs | 96 assays | 866.4 EUR |
|
Description: Our CytoSelect 96-Well Cell Transformation Assay (Soft Agar Colony Formation) is suitable for measuring cell transformation where no downstream analysis is required. Cells are incubated in a semisolid agar medium for 7-8 days. The cells are then solubilized, lysed and detected using the included fluorescent dye in a fluorometric plate reader. |
|||
CytoSelect 96-well Cell Transformation Assay |
|||
| CBA-130-5 | Cell Biolabs | 5 x 96 assays | 3463.2 EUR |
|
Description: Our CytoSelect 96-Well Cell Transformation Assay (Soft Agar Colony Formation) is suitable for measuring cell transformation where no downstream analysis is required. Cells are incubated in a semisolid agar medium for 7-8 days. The cells are then solubilized, lysed and detected using the included fluorescent dye in a fluorometric plate reader. |
|||
CytoSelect 24-well Cell Invasion, Fluorometric |
|||
| CBA-111 | Cell Biolabs | 12 assays | 714 EUR |
|
Description: The ability of malignant tumor cells to invade normal surrounding tissue contributes in large part to the morbidity and mortality of cancers. Cell invasion requires several distinct cellular functions including adhesion, motility, detachment, and extracellular matrix proteolysis. Our CytoSelect Cell Invasion Assays utilize precoated inserts to assay the invasive properties of tumor cells. Invasive cells can be quantified in 24-well plates on either a standard microplate reader or a fluorescence plate reader. Inserts are precoated on the top of the membrane with ECM matrix gel (basement membrane), a protein mix isolated from EHS tumor cells. |
|||
CytoSelect 96-well Cell Invasion, Fluorometric |
|||
| CBA-112 | Cell Biolabs | 96 assays | 908.4 EUR |
|
Description: The ability of malignant tumor cells to invade normal surrounding tissue contributes in large part to the morbidity and mortality of cancers. Cell invasion requires several distinct cellular functions including adhesion, motility, detachment, and extracellular matrix proteolysis. Our CytoSelect 96-Well Cell Invasion Assays utilize precoated inserts to assay the invasive properties of tumor cells. Invasive cells can be quantified in 96-well plates on a fluorescence plate reader. Inserts are precoated on the top of the membrane with Basement Membrane, an ECM protein mix isolated from EHS tumor cells. |
|||
CytoSelect Cell Viability and Cytotoxicity Assay |
|||
| CBA-240 | Cell Biolabs | 96 assays | 470.4 EUR |
|
Description: The CytoSelect Cell Viability and Cytotoxicity Assay Kit provides a simple format for monitoring cell viability via metabolic activity. Live cells are detected with either MTT (colorimetric detection) or Calcein AM (fluorometric detection). Dead cells are detected by EthD-1 reagent (fluorometric). All 3 detection reagents are included, along with Saponin (a cell death initiator). Prior to the assay, cells may be treated with compounds or agents that affect cell viability. This kit is suitable for eukaryotic cells, not yeast or bacteria. |
|||
RRAD Blocking Peptide |
|||
| 20-abx063234 | Abbexa |
|
|
RRAD Blocking Peptide |
|||
| 33R-10070 | Fitzgerald | 100 ug | 216 EUR |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of RRAD antibody, catalog no. 70R-5798 |
|||
Changes in Hb concentrations have been evaluated, and the proportion of sufferers with baseline anemia who have been now not anemic at week 24 was decided, as was the incidence of polycythemia (Hb >16.5 g/dL in males and >16.Zero g/dL in girls). Because anemia generally happens in sufferers with diabetes and persistent kidney illness [6], the info may be of worth to additional analyze traits in related physiological and pathophysiological parameters.